Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Skin-resident memory T cells as a potential new therapeutic target in vitiligo and melanoma.

Willemsen M, Linkutė R, Luiten RM, Matos TR.

Pigment Cell Melanoma Res. 2019 Sep;32(5):612-622. doi: 10.1111/pcmr.12803. Epub 2019 Jul 8. Review.

PMID:
31230406
2.

Tissue patrol by resident memory CD8+ T cells in human skin.

Dijkgraaf FE, Matos TR, Hoogenboezem M, Toebes M, Vredevoogd DW, Mertz M, van den Broek B, Song JY, Teunissen MBM, Luiten RM, Beltman JB, Schumacher TN.

Nat Immunol. 2019 Jun;20(6):756-764. doi: 10.1038/s41590-019-0404-3. Epub 2019 May 20.

PMID:
31110315
3.

Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.

Ouwerkerk W, van den Berg M, van der Niet S, Limpens J, Luiten RM.

Melanoma Res. 2019 Oct;29(5):453-464. doi: 10.1097/CMR.0000000000000589.

4.

Mechanism of action of 4-substituted phenols to induce vitiligo and antimelanoma immunity.

Kammeyer A, Willemsen KJ, Ouwerkerk W, Bakker WJ, Ratsma D, Pronk SD, Smit NPM, Luiten RM.

Pigment Cell Melanoma Res. 2019 Jul;32(4):540-552. doi: 10.1111/pcmr.12774. Epub 2019 Mar 18.

PMID:
30767390
5.

T-cell responses against 4-tert-butylphenol-exposed pigmented cells in a patient with occupational vitiligo.

Vrijman C, Willemsen KJ, Tjin EPM, Kammeyer A, van den Boorn JG, van der Veen JPW, Jungbauer FHW, Kardaun SH, Luiten RM.

Br J Dermatol. 2019 Aug;181(2):387-388. doi: 10.1111/bjd.17713. Epub 2019 Apr 7. No abstract available.

PMID:
30719700
6.

Expression of cancer/testis antigens in cutaneous melanoma: a systematic review.

Tio D, Kasiem FR, Willemsen M, van Doorn R, van der Werf N, Hoekzema R, Luiten RM, Bekkenk MW.

Melanoma Res. 2019 Aug;29(4):349-357. doi: 10.1097/CMR.0000000000000569.

PMID:
30615012
7.

Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.

Eby JM, Smith AR, Riley TP, Cosgrove C, Ankney CM, Henning SW, Paulos CM, Garrett-Mayer E, Luiten RM, Nishimura MI, Baker BM, Le Poole IC.

Pigment Cell Melanoma Res. 2019 Jan;32(1):68-78. doi: 10.1111/pcmr.12724. Epub 2018 Aug 13.

PMID:
30009548
8.

Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.

Teulings HE, Tjin EPM, Willemsen KJ, van der Kleij S, Ter Meulen S, Kemp EH, Krebbers G, van Noesel CJM, Franken CLMC, Drijfhout JW, Melief CJM, Nieuweboer-Krobotova L, Nieweg OE, van der Hage JA, van der Veen JPW, Relyveld GN, Luiten RM.

Oncoimmunology. 2018 Jan 15;7(4):e1419113. doi: 10.1080/2162402X.2017.1419113. eCollection 2018.

9.

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.

Jessurun CAC, Vos JAM, Limpens J, Luiten RM.

Front Oncol. 2017 Sep 27;7:233. doi: 10.3389/fonc.2017.00233. eCollection 2017.

10.

House dust mite allergens Der f and Der p induce IL-31 production by blood-derived T cells from atopic dermatitis patients.

Szegedi K, van Lier A, Res PC, Chielie S, Bos JD, Kezic S, Middelkamp-Hup MA, Luiten RM.

Exp Dermatol. 2018 Apr;27(4):393-395. doi: 10.1111/exd.13438. Epub 2017 Nov 7.

PMID:
28887844
11.

Autologous cell suspension grafting in segmental vitiligo and piebaldism: a randomized controlled trial comparing full surface and fractional CO2 laser recipient-site preparations.

Lommerts JE, Meesters AA, Komen L, Bekkenk MW, de Rie MA, Luiten RM, Wolkerstorfer A.

Br J Dermatol. 2017 Nov;177(5):1293-1298. doi: 10.1111/bjd.15569. Epub 2017 Oct 22.

PMID:
28403523
12.

Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants.

Jin Y, Andersen G, Yorgov D, Ferrara TM, Ben S, Brownson KM, Holland PJ, Birlea SA, Siebert J, Hartmann A, Lienert A, van Geel N, Lambert J, Luiten RM, Wolkerstorfer A, Wietze van der Veen JP, Bennett DC, Taïeb A, Ezzedine K, Kemp EH, Gawkrodger DJ, Weetman AP, Kõks S, Prans E, Kingo K, Karelson M, Wallace MR, McCormack WT, Overbeck A, Moretti S, Colucci R, Picardo M, Silverberg NB, Olsson M, Valle Y, Korobko I, Böhm M, Lim HW, Hamzavi I, Zhou L, Mi QS, Fain PR, Santorico SA, Spritz RA.

Nat Genet. 2016 Nov;48(11):1418-1424. doi: 10.1038/ng.3680. Epub 2016 Oct 10.

13.

Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field.

Lommerts JE, Teulings HE, Ezzedine K, van Geel N, Hartmann A, Speeckaert R, Spuls PI, Wolkerstorfer A, Luiten RM, Bekkenk MW.

J Am Acad Dermatol. 2016 Dec;75(6):1198-1204. doi: 10.1016/j.jaad.2016.07.060. Epub 2016 Oct 4.

PMID:
27717621
14.

Optimising size and depth of punch grafts in autologous transplantation of vitiligo and piebaldism: a randomised controlled trial.

Komen L, Vrijman C, Prinsen CA, van der Veen JP, Luiten RM, Wolkerstorfer A.

J Dermatolog Treat. 2017 Feb;28(1):86-91. doi: 10.1080/09546634.2016.1179251. Epub 2016 Jun 16.

PMID:
27309418
15.

Inflammasome-Dependent Induction of Adaptive NK Cell Memory.

van den Boorn JG, Jakobs C, Hagen C, Renn M, Luiten RM, Melief CJ, Tüting T, Garbi N, Hartmann G, Hornung V.

Immunity. 2016 Jun 21;44(6):1406-21. doi: 10.1016/j.immuni.2016.05.008. Epub 2016 Jun 7.

16.

Vitiligo-like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre.

Teulings HE, Lommerts JE, Wolkerstorfer A, Nieuweboer-Krobotova L, Luiten RM, Bekkenk MW, van der Veen JP.

Br J Dermatol. 2017 Feb;176(2):503-506. doi: 10.1111/bjd.14790. Epub 2016 Nov 11. No abstract available.

PMID:
27273338
17.

Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥ 50 years.

Teulings HE, Ceylan E, Overkamp M, Vrijman C, Bos JD, Nijsten TE, Wolkerstorfer A, Luiten RM, van der Veen JP.

Br J Dermatol. 2016 Oct;175(4):821-4. doi: 10.1111/bjd.14640. Epub 2016 Aug 3. No abstract available.

PMID:
27042816
18.

Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin.

Klarquist J, Eby JM, Henning SW, Li M, Wainwright DA, Westerhof W, Luiten RM, Nishimura MI, Le Poole IC.

Pigment Cell Melanoma Res. 2016 May;29(3):379-84. doi: 10.1111/pcmr.12458. Epub 2016 Mar 4.

19.

Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: A randomized controlled pilot study.

Komen L, Vrijman C, Tjin EP, Krebbers G, de Rie MA, Luiten RM, van der Veen JP, Wolkerstorfer A.

J Am Acad Dermatol. 2015 Jul;73(1):170-2. doi: 10.1016/j.jaad.2015.03.036. No abstract available.

PMID:
26089056
20.

Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin.

Szegedi K, Lutter R, Res PC, Bos JD, Luiten RM, Kezic S, Middelkamp-Hup MA.

J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2136-44. doi: 10.1111/jdv.13160. Epub 2015 May 18.

PMID:
25980674
21.

Tumor-infiltrating T-cells: important players in clinical outcome of advanced melanoma patients.

Tjin EP, Luiten RM.

Oncoimmunology. 2014 Dec 13;3(9):e954862. eCollection 2014 Sep.

22.

Oxidation events and skin aging.

Kammeyer A, Luiten RM.

Ageing Res Rev. 2015 May;21:16-29. doi: 10.1016/j.arr.2015.01.001. Epub 2015 Jan 31. Review.

PMID:
25653189
23.

Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM.

J Clin Oncol. 2015 Mar 1;33(7):773-81. doi: 10.1200/JCO.2014.57.4756. Epub 2015 Jan 20. Review.

PMID:
25605840
24.

The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.

Teulings HE, Willemsen KJ, Glykofridis I, Krebbers G, Komen L, Kroon MW, Kemp EH, Wolkerstorfer A, van der Veen JP, Luiten RM, Tjin EP.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1086-96. doi: 10.1111/pcmr.12294. Epub 2014 Aug 4.

PMID:
25043574
25.

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Cancer Immunol Res. 2014 Jun;2(6):538-46. doi: 10.1158/2326-6066.CIR-13-0097. Epub 2014 Mar 10.

26.

Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.

Webb KC, Eby JM, Hariharan V, Hernandez C, Luiten RM, Le Poole IC.

Exp Dermatol. 2014 Aug;23(8):529-33. doi: 10.1111/exd.12449. Epub 2014 Jul 10.

27.

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo.

Kroon MW, Vrijman C, Chandeck C, Wind BS, Wolkerstorfer A, Luiten RM, Bos JD, Geskus RB, van Trotsenburg P, van der Veen JP.

Horm Res Paediatr. 2013;79:137-44. doi: 10.1159/000348388. Epub 2013 Mar 19.

PMID:
23548513
28.

Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis.

Teulings HE, Tjin EP, Willemsen KJ, Krebbers G, van Noesel CJ, Kemp EH, Nieuweboer-Krobotova L, van der Veen JP, Luiten RM.

Br J Dermatol. 2013 Apr;168(4):733-8. doi: 10.1111/bjd.12136. Epub 2013 Feb 27.

PMID:
23421690
29.

Provoking factors, including chemicals, in Dutch patients with vitiligo.

Vrijman C, Hosseinpour D, Bakker JG, Wolkerstorfer A, Bos JD, van der Veen JP, Luiten RM.

Br J Dermatol. 2013 May;168(5):1003-11. doi: 10.1111/bjd.12162.

PMID:
23252956
30.

Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners.

Teulings HE, Overkamp M, Ceylan E, Nieuweboer-Krobotova L, Bos JD, Nijsten T, Wolkerstorfer AW, Luiten RM, van der Veen JP.

Br J Dermatol. 2013 Jan;168(1):162-71. doi: 10.1111/bjd.12111.

PMID:
23136900
31.

The prevalence of thyroid disease in patients with vitiligo: a systematic review.

Vrijman C, Kroon MW, Limpens J, Leeflang MM, Luiten RM, van der Veen JP, Wolkerstorfer A, Spuls PI.

Br J Dermatol. 2012 Dec;167(6):1224-35. doi: 10.1111/j.1365-2133.2012.11198.x. Epub 2012 Oct 5. Review.

PMID:
22860695
32.

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells.

Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, Michaux A, Ma W, Mulder A, Van den Eynde BJ, van der Bruggen P, Vigneron N.

Eur J Immunol. 2012 Jun;42(6):1417-28. doi: 10.1002/eji.201141954.

33.

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin.

Szegedi K, Kremer AE, Kezic S, Teunissen MB, Bos JD, Luiten RM, Res PC, Middelkamp-Hup MA.

Exp Dermatol. 2012 Jun;21(6):431-6. doi: 10.1111/j.1600-0625.2012.01487.x.

PMID:
22621183
34.

Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo.

Jin Y, Birlea SA, Fain PR, Ferrara TM, Ben S, Riccardi SL, Cole JB, Gowan K, Holland PJ, Bennett DC, Luiten RM, Wolkerstorfer A, van der Veen JP, Hartmann A, Eichner S, Schuler G, van Geel N, Lambert J, Kemp EH, Gawkrodger DJ, Weetman AP, Taïeb A, Jouary T, Ezzedine K, Wallace MR, McCormack WT, Picardo M, Leone G, Overbeck A, Silverberg NB, Spritz RA.

Nat Genet. 2012 May 6;44(6):676-80. doi: 10.1038/ng.2272.

35.

Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo.

Kroon MW, Kemp EH, Wind BS, Krebbers G, Bos JD, Gawkrodger DJ, Wolkerstorfer A, van der Veen JP, Luiten RM.

J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1172-5. doi: 10.1111/j.1468-3083.2012.04501.x. Epub 2012 Mar 10.

PMID:
22404127
36.

Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes.

Weder P, Schumacher TN, Spits H, Luiten RM.

Results Immunol. 2012 May 10;2:88-96. doi: 10.1016/j.rinim.2012.04.001. eCollection 2012.

37.

Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.

Speeckaert R, van Geel N, Luiten RM, van Gele M, Speeckaert M, Lambert J, Vermaelen K, Tjin EP, Brochez L.

Anticancer Res. 2011 Nov;31(11):3697-703.

PMID:
22110189
38.

Low yield of routine screening for thyroid dysfunction in asymptomatic patients with vitiligo.

Kroon MW, Joore IC, Wind BS, Leloup MA, Wolkerstorfer A, Luiten RM, Bos JD, Geskus RB, van der Veen JP.

Br J Dermatol. 2012 Mar;166(3):532-8. doi: 10.1111/j.1365-2133.2011.10717.x.

PMID:
22050082
39.

In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial.

van Geel N, Speeckaert R, Mollet I, De Schepper S, De Wolf J, Tjin EP, Luiten RM, Lambert J, Brochez L.

Pigment Cell Melanoma Res. 2012 Jan;25(1):57-65. doi: 10.1111/j.1755-148X.2011.00922.x. Epub 2011 Nov 2.

PMID:
21982055
40.

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.

Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE, Kroon BB, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Clin Cancer Res. 2011 Sep 1;17(17):5736-47. doi: 10.1158/1078-0432.CCR-11-0230. Epub 2011 Jul 12.

41.

Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.

van den Boorn JG, Melief CJ, Luiten RM.

Pigment Cell Melanoma Res. 2011 Aug;24(4):673-9. doi: 10.1111/j.1755-148X.2011.00878.x. Epub 2011 Jul 6. Review.

PMID:
21689385
42.

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.

van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, van Capel T, Jong EC, Reits EA, Drijfhout JW, Bos JD, Melief CJ, Luiten RM.

J Invest Dermatol. 2011 Jun;131(6):1240-51. doi: 10.1038/jid.2011.16. Epub 2011 Feb 17.

43.

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.

van den Boorn JG, Konijnenberg D, Tjin EP, Picavet DI, Meeuwenoord NJ, Filippov DV, van der Veen JP, Bos JD, Melief CJ, Luiten RM.

PLoS One. 2010 May 13;5(5):e10626. doi: 10.1371/journal.pone.0010626.

44.

First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi.

van Geel NA, Mollet IG, De Schepper S, Tjin EP, Vermaelen K, Clark RA, Kupper TS, Luiten RM, Lambert J.

Pigment Cell Melanoma Res. 2010 Jun;23(3):375-84. doi: 10.1111/j.1755-148X.2010.00703.x. Epub 2010 Apr 1.

PMID:
20370855
45.

Skin immune system.

Bos JD, Luiten RM.

Cancer Treat Res. 2009;146:45-62. doi: 10.1007/978-0-387-78574-5_5. Review. No abstract available.

PMID:
19415192
46.

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.

van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM.

J Invest Dermatol. 2009 Sep;129(9):2220-32. doi: 10.1038/jid.2009.32. Epub 2009 Feb 26.

47.

Autoimmune etiology of generalized vitiligo.

Le Poole IC, Luiten RM.

Curr Dir Autoimmun. 2008;10:227-43. doi: 10.1159/000131485. Review.

PMID:
18460889
48.

Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?

Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, Giachino C, Liu JB, Luiten RM, Lambe T, Le Poole IC, Dammak I, Onay H, Zmijewski MA, Dell'Anna ML, Zeegers MP, Cornall RJ, Paus R, Ortonne JP, Westerhof W.

Exp Dermatol. 2008 Feb;17(2):139-40; discussion 141-60. doi: 10.1111/j.1600-0625.2007.00666_1.x.

PMID:
18205713
49.

Therapeutic implications of autoimmune vitiligo T cells.

Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, Le Poole IC.

Autoimmun Rev. 2006 Aug;5(7):486-92. Epub 2006 May 6. Review.

50.

T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity.

van den Boorn JG, Le Poole IC, Luiten RM.

Int Rev Immunol. 2006 May-Aug;25(3-4):235-58. Review.

Supplemental Content

Loading ...
Support Center